Detail akcie Candel Therapeut Rg online

Business Summary: Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Candel Therapeutics Inc revenues was not reported. Net loss decreased 79% to $8.7M. Lower net loss reflects oncolytic viral immunotherapies segment loss decrease of 23% to $19.3M, United States segment loss decrease of 23% to $19.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.36 to -$0.15.